PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS
- Conditions
- Prader-Willi Syndrome
- Interventions
- Biological: somatropin - GH naïve pediatric cohortBiological: somatropin - GH treated cohortBiological: somatropin - adult cohort
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 33
- Registration Number
- NCT04697381
- Locations
- 🇯🇵
Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan
🇯🇵Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan
🇯🇵Osaka Women's and Children's Hospital, Izumi, Osaka, Japan
To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma
- Conditions
- Renal Cell Carcinoma
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 481
- Registration Number
- NCT04682587
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 108
- Registration Number
- NCT04682639
- Locations
- 🇺🇸
Mile Square Surgery Center, Fountain Valley, California, United States
🇺🇸Bay Area Chest Physicians, P.A., - Pulmonary Function Test, Clearwater, Florida, United States
🇺🇸Dothan Eyecare - Dr. Brent McKinley (OCT Procedure Only), Dothan, Alabama, United States
Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 107383
- Registration Number
- NCT04681482
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorsBreast CancerPancreatic CancerSolid TumorsOvarian CancerProstate CancerColorectal CancerNSCLC
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 73
- Registration Number
- NCT04672460
- Locations
- 🇺🇸
Mary Crowley Cancer Research - Medical City Hospital, Dallas, Texas, United States
🇺🇸West Chester Hospital, West Chester, Ohio, United States
🇺🇸California Cancer Associates for Research and Excellence, Inc (cCARE), San Marcos, California, United States
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 559
- Registration Number
- NCT04671615
- Locations
- 🇮🇱
Pfizer Pharmaceuticals Israel Ltd., Herzliya Pituach, Israel
Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 121
- Registration Number
- NCT04668066
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸First OC Dermatology, Fountain Valley, California, United States
🇺🇸Keck School of Medicine of USC, Los Angeles, California, United States
Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1205
- Registration Number
- NCT04669366
- Locations
- 🇸🇪
Pfizer Innovations AB, Sollentuna, Sweden
Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis
- Conditions
- Atopic DermatitisPlaque Psoriasis
- Interventions
- Drug: PF-07038124 ointmentDrug: Vehicle ointment
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 104
- Registration Number
- NCT04664153
- Locations
- 🇺🇸
Center for Clinical Studies, Houston, Texas, United States
🇵🇱Mazowieckie Centrum Badań Klinicznych, Grodzisk Mazowiecki, Poland
🇵🇱Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna, Lodz, Poland
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 256
- Registration Number
- NCT04657991
- Locations
- 🇩🇪
HELIOS Klinikum Erfurt, Erfurt, Germany
🇺🇸UCLA - Hematology/Oncology - Administrative Office, Los Angeles, California, United States
🇺🇸Ronald Reagan UCLA Medical Center Drug Information Center , Dept. of Pharmaceutical Services (Drug, Los Angeles, California, United States